RPG Life Sciences (NSE:RPGLIFE) Piotroski F-Score: 3 (As of Jun. 29, 2026) — 57% Below Median


NSE:RPGLIFE RPG Life Sciences Ltd NSE:RPGLIFE
92 GF Score
Price ₹2,276.40
GF Value ₹2,359.83
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is RPG Life Sciences Piotroski F-Score?

RPG Life Sciences NSE:RPGLIFE -0.54% 92 Piotroski F-Score is 3 as of Jun. 29, 2026, which is 57% below its 10-year median of 7.00. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,359.83 (Fairly Valued). The stock has 3 warning signs investors should review. Among 978 Drug Manufacturers companies, RPG Life Sciences ranks worse than 78.12% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

RPG Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for RPG Life Sciences's Piotroski F-Score or its related term are showing as below:

NSE:RPGLIFE' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 7   Max: 9
Current: 3

During the past 13 years, the highest Piotroski F-Score of RPG Life Sciences was 9. The lowest was 3. And the median was 7.

RPG Life Sciences  (NSE:RPGLIFE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


RPG Life Sciences Piotroski F-Score Related Terms


RPG Life Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for RPG Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RPG Life Sciences Piotroski F-Score Chart

RPG Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.00 7.00 7.00 7.00 3.00

RPG Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 0.00 0.00 3.00

NSE:RPGLIFE vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RPG Life Sciences Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where RPG Life Sciences's Piotroski F-Score falls into.


NSE:RPGLIFE
92GF Score
RPG Life Sciences Ltd NSE:RPGLIFE
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹1,152 Mil.
Cash Flow from Operations was ₹565 Mil.
Revenue was ₹7,075 Mil.
Gross Profit was ₹4,554 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (6578.1 + 7931.6) / 2 = ₹7254.85 Mil.
Total Assets at the begining of this year (Mar25) was ₹6,578 Mil.
Long-Term Debt & Capital Lease Obligation was ₹133 Mil.
Total Current Assets was ₹5,595 Mil.
Total Current Liabilities was ₹1,606 Mil.
Net Income was ₹1,832 Mil.

Revenue was ₹6,534 Mil.
Gross Profit was ₹4,394 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (5128.7 + 6578.1) / 2 = ₹5853.4 Mil.
Total Assets at the begining of last year (Mar24) was ₹5,129 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹4,653 Mil.
Total Current Liabilities was ₹1,198 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

RPG Life Sciences's current Net Income (TTM) was 1,152. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

RPG Life Sciences's current Cash Flow from Operations (TTM) was 565. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1151.7/6578.1
=0.17508095

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1832.4/5128.7
=0.35728352

RPG Life Sciences's return on assets of this year was 0.17508095. RPG Life Sciences's return on assets of last year was 0.35728352. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

RPG Life Sciences's current Net Income (TTM) was 1,152. RPG Life Sciences's current Cash Flow from Operations (TTM) was 565. ==> 565 <= 1,152 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=133.3/7254.85
=0.01837392

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/5853.4
=0

RPG Life Sciences's gearing of this year was 0.01837392. RPG Life Sciences's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=5594.8/1605.7
=3.48433705

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4652.5/1198.3
=3.88258366

RPG Life Sciences's current ratio of this year was 3.48433705. RPG Life Sciences's current ratio of last year was 3.88258366. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

RPG Life Sciences's number of shares in issue this year was 16.538. RPG Life Sciences's number of shares in issue last year was 16.538. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4554.3/7075.2
=0.64369912

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4394.2/6534.3
=0.67248213

RPG Life Sciences's gross margin of this year was 0.64369912. RPG Life Sciences's gross margin of last year was 0.67248213. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=7075.2/6578.1
=1.07556893

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=6534.3/5128.7
=1.27406555

RPG Life Sciences's asset turnover of this year was 1.07556893. RPG Life Sciences's asset turnover of last year was 1.27406555. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

RPG Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
RPG Life Sciences (NSE:RPGLIFE) has a Piotroski F-Score of 3 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on RPG Life Sciences and its competitors. This is 57% below median its historical median of 7.00. Over the past decade, RPG Life Sciences' Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, RPG Life Sciences ranks #764 out of 978 companies in the Drug Manufacturers industry, placing it in the top 78.1%.
Is RPG Life Sciences' Piotroski F-Score too high?
RPG Life Sciences' current Piotroski F-Score of 3 is 57% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. RPG Life Sciences' value of 3 is 40% below this industry median. Based on the distribution chart, RPG Life Sciences ranks #764 out of 978 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #764 out of 978 companies for Piotroski F-Score. This places RPG Life Sciences in the lower half of its industry. The industry median Piotroski F-Score is 5.00. RPG Life Sciences' value of 3 is 40% below this benchmark. Historically, RPG Life Sciences' own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, RPG Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current Piotroski F-Score is 3, which is 57% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,359.83, compared to a current price of ₹2,276.40 — trading 3.5% below its estimated fair value. The current Piotroski F-Score is 3, which is 57% below median its 10-year median of 7.00 and 40% below the Drug Manufacturers industry median of 5.00. RPG Life Sciences' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current Piotroski F-Score is 3 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, RPG Life Sciences stock appears to be undervalued. The current stock price of ₹2,276.40 is trading 3.5% below its estimated GF Value™ of ₹2,359.83. GuruFocus considers RPG Life Sciences to be Fairly Valued.

Key valuation signals for NSE:RPGLIFE:

  • Piotroski F-Score: 3 (57% below median its 10-year median of 7.00)
  • GF Value™: ₹2,359.83 vs. price of ₹2,276.40 (3.5% below fair value)
  • GF Score™: 92/100 with 3 warning signs
  • Industry Position: 40% below the Drug Manufacturers median (#764 of 978)

No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RPG Life Sciences Business Description

Other Exchanges 532983:India
Address 463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score

Get the complete analysis for NSE:RPGLIFE

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,276.40
Price
₹2,359.83
GF Value